NMO exacerbation has been reported in patients treated with MS disease-modifying therapies who were subsequently found to be anti-AQP4 antibody-positive [12], and in whom the initial diagnosis of MS was changed to NMO [13]. Here, AQP4 is linked to myeloid sarcoma.